(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
...
...
Sangamo Therapeutics (SGMO) said Thursday that the European Commission has granted an orphan medicinal product designation to its chimeric antigen receptor...
| Address | 7000 Marina Boulevard Brisbane, California 94005 |
| Phone | +1.510.970.6000 |
| Number of Employees | 302 |
| Recent SEC Filing | 08/09/2022 8-K |
| President, Chief Executive Officer & Director | Alexander D. Macrae |
| Chief Operating Officer & Executive Vice President | Mark D. McClung |
| Senior VP, Chief Financial & Accounting Officer | Prathyusha Durabaibu |
| Executive Vice President-Technical Operations | R. Andrew Ramelmeier |
| Price Open | $5.40 |
| Previous Close | $5.24 |
| 52 Week Range | $3.12 - 11.49 |
| Market Capitalization | $915.8 M |
| Shares Outstanding | 156.6 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/03/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.18 |
| Beta vs. S&P 500 | N/A |
| Revenue | $84.5 M |
| Net Profit Margin | -150.96% |
| Return on Equity | -48.07% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
